The associations of psoas and masseter muscles with sarcopenia and related adverse outcomes in older trauma patients: a retrospective study

File Description SizeFormat 
Varma et al. 2022 Aging Clinical and Experimental Research.pdfPublished version592.18 kBAdobe PDFView/Open
Title: The associations of psoas and masseter muscles with sarcopenia and related adverse outcomes in older trauma patients: a retrospective study
Authors: Varma, S
Wilson, MSJ
Naik, M
Sandhu, A
Ota, HCU
Aylwin, C
Fertleman, M
Peck, G
Item Type: Journal Article
Abstract: Background There is an emerging role for radiological evaluation of psoas muscle as a marker of sarcopenia in trauma patients. Older trauma patients are more likely to undergo cranial than abdomino-pelvic imaging. Identifying sarcopenia using masseter cross-sectional area (M-CSA) has shown correlation with mortality. We sought to determine the correlation between psoas: lumbar vertebral index (PLVI) and the M-CSA, and their association with health outcomes. Methods Patients aged 65 or above, who presented as a trauma call over a 1-year period were included if they underwent cranial or abdominal CT imaging. Images were retrospectively analysed to obtain PLVI and mean M-CSA measurements. Electronic records were abstracted for outcomes. Logistic regression methods, log scale analyses, Cox regression model and Kaplan–Meier plots were used to determine association of sarcopenia with outcomes. Results There were 155 eligible patients in the M-CSA group and 204 patients in the PLVI group. Sarcopenia was defined as the lowest quartile in each group. Pearson’s correlation indicated a weakly positive linear relationship (r = 0.35, p < 0.001) between these. There was no statistical association between M-CSA sarcopenia status and any measured outcomes. Those with PLVI sarcopenia were more likely to die in hospital (adjusted OR 3.38, 95% CI 1.47–9.73, p = 0.006) and at 2 years (adjusted HR 1.90, 95% CI 1.11–3.25, p = 0.02). Only 29% patients with PLVI sarcopenia were discharged home, compared with 58% without sarcopenia (p = 0.001). Conclusion Sarcopenia, defined by PLVI, is predictive of increased in-patient and 2-year mortality. Our study did not support prognostic relevance of M-CSA.
Issue Date: 31-Mar-2022
Date of Acceptance: 14-Mar-2022
URI: http://hdl.handle.net/10044/1/96165
DOI: 10.1007/s40520-022-02119-7
ISSN: 1594-0667
Publisher: Springer
Journal / Book Title: Aging Clinical and Experimental Research
Volume: 34
Copyright Statement: © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Keywords: Science & Technology
Life Sciences & Biomedicine
Geriatrics & Gerontology
Sarcopenia
Psoas
Masseter
Elderly trauma
Frailty
TEMPORALIS MUSCLE
PREDICTOR
MORTALITY
Elderly trauma
Frailty
Masseter
Psoas
Sarcopenia
Aged
Humans
Masseter Muscle
Psoas Muscles
Retrospective Studies
Risk Factors
Sarcopenia
1103 Clinical Sciences
1117 Public Health and Health Services
1702 Cognitive Sciences
Geriatrics
Publication Status: Published online
Online Publication Date: 2022-03-31
Appears in Collections:Department of Metabolism, Digestion and Reproduction
Bioengineering
Faculty of Medicine
Faculty of Engineering



This item is licensed under a Creative Commons License Creative Commons